Moreover, SCS engages adenosine receptor pathways to normalize tactile thresholds [19], and chronic pain conditions such as diabetic neuropathy may limit SCS efficacy due to reduced KCC2 expression and impaired GABA(A)-mediated inhibition [17]. Here, SLC12A5 is linked to diabetic neuropathy.